Alzheimer's disease, Neurodegenerative disease
COYACoya TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for COYA 301 (Low Dose IL-2) in Alzheimer's disease, Neurodegenerative disease. The expected timing is based on the latest available company guidance and may change.
5/22/24- IIT study completed. 10/29/24- Presented result at CTAD'24. 10/29/24- Met primary and secondary endpoints. 11/12/25- 21wk exploratory Ph2 study completed; additional single-cell proteomics data to follow. 12/09/25:- PR No update. 03/16/26:- Additional single-cell proteomics data from completed AD IIT exploratory Ph2 study expected in H2 2026. 05/12/26:- Additional single-cell proteomics data from completed AD IIT still expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.